Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on rare and orphan diseases. Its sole product, Endari (prescription grade L-glutamine oral powder), is FDA-approved to reduce acute complications of sickle cell disease in adults and pediatric patients aged five and older. Endari is also approved in UAE, Qatar, Kuwait, Bahrain, and Oman, and sold through distributors in the U.S. and MENA region.
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-132925 | EDGAR | 59K words |
| 2025-04-14 | 2024-12-31 | 0000950170-25-053744 | EDGAR | — |
| 2024-07-03 | 2023-12-31 | 0000950170-24-080918 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0000950170-23-011328 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001564590-22-013054 | EDGAR | — |
| 2021-05-04 | 2020-12-31 | 0001564590-21-022930 | EDGAR | — |
| 2021-01-25 | 2019-12-31 | 0001564590-21-001977 | EDGAR | — |
| 2018-12-11 | 2018-09-30 | 0001615774-18-014245 | EDGAR | — |
| 2017-12-29 | 2017-09-30 | 0001615774-17-007691 | EDGAR | — |
| 2016-12-22 | 2016-09-30 | 0001615774-16-009049 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-282675 | EDGAR | 23K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108770 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072520 | EDGAR | — |
| 2024-11-19 | 2024-09-30 | 0000950170-24-128621 | EDGAR | — |
| 2024-09-10 | 2024-06-30 | 0000950170-24-105016 | EDGAR | — |
| 2024-09-10 | 2024-03-31 | 0000950170-24-105004 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063225 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042300 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021891 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001564590-22-037658 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001564590-22-029481 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001564590-22-019955 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001213900-26-036886 | EDGAR | 2K words |
| 2026-03-04 | 0001213900-26-023644 | EDGAR | — |
| 2025-12-31 | 0001213900-25-126728 | EDGAR | — |
| 2025-12-22 | 0001213900-25-124513 | EDGAR | — |
| 2025-12-19 | 0001213900-25-123836 | EDGAR | — |
| 2025-11-14 | 0001213900-25-110878 | EDGAR | — |
| 2025-08-14 | 0001213900-25-076672 | EDGAR | — |
| 2025-07-01 | 0001213900-25-060349 | EDGAR | — |
| 2025-05-15 | 0001213900-25-044286 | EDGAR | — |
| 2025-05-06 | 0001213900-25-039783 | EDGAR | — |
353 total filings indexed. 321 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000822370 |
| Ticker | EMMA |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report